

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://FDILab.org) on May 7, 2025

PE/Dazzle(TM) 594 anti-human IgM

RRID:AB_2566483

Type: Antibody

Proper Citation

(BioLegend Cat# 314530, RRID:AB_2566483)

Antibody Information

URL: http://antibodyregistry.org/AB_2566483

Proper Citation: (BioLegend Cat# 314530, RRID:AB_2566483)

Target Antigen: IgM

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Dazzle(TM) 594 anti-human IgM

Description: This monoclonal targets IgM

Target Organism: human

Clone ID: Clone MHM-88

Antibody ID: AB_2566483

Vendor: BioLegend

Catalog Number: 314530

Alternative Catalog Numbers: 314529

Record Creation Time: 20231110T035152+0000

Record Last Update: 20240725T100617+0000

Ratings and Alerts

No rating or validation information has been found for PE/Dazzle(TM) 594 anti-human IgM.

No alerts have been found for PE/Dazzle(TM) 594 anti-human IgM.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Dyikanov D, et al. (2024) Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer. *Cancer cell*, 42(5), 759.

Mayer-Blackwell K, et al. (2023) mRNA vaccination boosts S-specific T cell memory and promotes expansion of CD45RA^{int} TEMRA-like CD8⁺ T cells in COVID-19 recovered individuals. *Cell reports. Medicine*, 4(8), 101149.

Jennewein MF, et al. (2021) Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. *Cell reports*, 36(2), 109353.

Cohen KW, et al. (2021) Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. *Cell reports. Medicine*, 2(7), 100354.

Seydoux E, et al. (2020) Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. *Immunity*, 53(1), 98.